Skip to main content
SpringerLink
Log in

Hepatotoxicity of Antitubercular Treatments

Rationale for Monitoring Liver Status

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

The standard antitubercular regimen currently includes a combination of 3 antitubercular agents: isoniazid, rifampicin (rifampin) and pyrazinamide. Administration of a fourth agent, ethambutol, is recommended when isoniazid resistance is suspected. Two of these 4 agents (isoniazid and pyrazinamide) are major hepatotoxins. The remaining 2 agents (rifampicin and ethambutol) are rarely or not hepatotoxic. However, rifampicin, which is a powerful enzyme inducer, may enhance the hepatotoxicity of isoniazid.

In patients receiving a combination of isoniazid, rifampicin and pyrazinamide, 2 patterns of fulminant liver injury can be observed. The first pattern is characterised by an increase in serum transaminase activity that occurs soon (usually within the first 15 days) after initiation of treatment. This pattern is likely to be caused by rifampicin-induced isoniazid hepatotoxicity. The prognosis is good in most cases. The second pattern is characterised by an increase in serum ransaminase activity that occurs late (usually more than 1 month) after the initiation of treatment. It has been suggested that this pattern may be related to pyrazinamide hepatotoxicity. The prognosis of this type of hepatitis is generally poor.

In order to reduce the risk of severe hepatic adverse effects during antitubercular treatment, several measures are proposed. First, patients with underlying liver test abnormalities should not be given pyrazinamide. Second, isoniazid and pyrazinamide should be administered at the lowest dosage within their respective therapeutic ranges. Third, serum transaminase levels should be determined twice weekly during the first 2 weeks of treatment, every 2 weeks during the rest of the first 2 months, and every month thereafter. When serum transaminase levels increase to greater than 3 times the upper limit of normal, therapy with isoniazid, rifampicin and pyrazinamide should be stopped.

After serum transaminase levels have returned to normal, isoniazid can be re-introduced at a low daily dose, without rifampicin. Pyrazinamide may not be re-introduced because of the risk of recurrence and the poor prognosis of pyrazinamide-induced hepatitis. Although it is nephrotoxic, streptomycin is an alternative in patients with liver test abnormalities during antitubercular treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jereb JA, Kelly GD, Dooley SW, et al. Tuberculosis morbidity in the United States: final data. MMWR Morb Mortal Wkly Rep 1991; 40(SS-3): 23–7

    CAS  Google Scholar 

  2. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multi-drug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137–44

    Article  PubMed  CAS  Google Scholar 

  3. David HL. Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810–4

    PubMed  CAS  Google Scholar 

  4. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514–21

    Article  PubMed  CAS  Google Scholar 

  5. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 146: 1623–33

    Google Scholar 

  6. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644–50

    Article  PubMed  CAS  Google Scholar 

  7. World Health Organization. Treatment of tuberculosis: guidelines for national programs. Geneva: World Health Organisation, 1993

    Google Scholar 

  8. Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol [letter]. Br Med J 1986; 292: 866

    Article  CAS  Google Scholar 

  9. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79: 1–12

    PubMed  CAS  Google Scholar 

  10. Schraer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 1: 1113–20

    Google Scholar 

  11. Black M, Mitchell JR, Zimmerman HJ. Isoniazid associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302

    PubMed  CAS  Google Scholar 

  12. Thomas PA, Mozes MF, Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979; 114: 597–9

    Article  PubMed  Google Scholar 

  13. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106: 357–65

    PubMed  CAS  Google Scholar 

  14. Bailey WC, Taylor SL, Dascomb HE, et al. Disturbed hepatic function during isoniazid chemoprophylaxis. Am Rev Respir Dis 1973; 107: 523–9

    PubMed  CAS  Google Scholar 

  15. Byrd CR, Horn BR, Solomon DA, et al. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients. JAMA 1979; 241: 1239–41

    Article  PubMed  CAS  Google Scholar 

  16. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a US public health service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991–1001

    PubMed  CAS  Google Scholar 

  17. Mitchell JR, Zimmerman HJ, Ishak KJ, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181–92

    PubMed  CAS  Google Scholar 

  18. Cohen R, Kaiser MH, Thomson RV. Fatal hepatic necrosis secondary to isoniazid therapy. JAMA 1961; 176: 877–9

    Article  PubMed  CAS  Google Scholar 

  19. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494–7

    PubMed  Google Scholar 

  20. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994

    Google Scholar 

  21. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferases induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295–8

    Article  PubMed  CAS  Google Scholar 

  22. Mitchell JR, Long MW, Thorgeirsson U, et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68: 181–90

    Article  PubMed  CAS  Google Scholar 

  23. Pessayre D, Bentata M, Degott C, et al. Isoniazid rifampicin induced fulminant hepatitis: a possible consequence of enhancement of hepatotoxicity by enzyme induction. Gastroenterology 1977; 72: 284–9

    PubMed  CAS  Google Scholar 

  24. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21: 929–32

    Article  PubMed  CAS  Google Scholar 

  25. Timbrell JA, Mitchell JR, Snodgrass WR, et al. Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213: 364–9

    PubMed  CAS  Google Scholar 

  26. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and significance for the treatment of tuberculosis. Clin Pharm Ther 1976; 19: 610–24

    CAS  Google Scholar 

  27. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129: 58–61

    PubMed  CAS  Google Scholar 

  28. Martinez-Roig A, Cami J, Llorens-Terol J, et al. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986; 77: 912–5

    PubMed  CAS  Google Scholar 

  29. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5: S440–5

    Article  PubMed  CAS  Google Scholar 

  30. Scheuer PJ, Summerfield JA, Lal S, et al. Rifampicin hepatitis: a clinical and histological study. Lancet 1974; I: 421–5

    Article  Google Scholar 

  31. Poupon RY, Meyniel D, Petit J, et al. Hépatite cholestatique au cours d’un traitement par l’INH et la rifampicine; arguments en faveur de l’hépatotoxicité de la rifampicine. Ann Med Interne (Paris) 1979; 130: 371–5

    CAS  Google Scholar 

  32. Furet Y, Metman EH, Bertrand J, et al. Hépatite mixte à la rifamycine SV [letter]. Therapie 1986; 41: 405

    PubMed  CAS  Google Scholar 

  33. McDermott W, Ormond L, Muschenheim C, et al. Pyrazinamide and isoniazid in tuberculosis. Am Rev Tuberc 1954; 69: 319–33

    PubMed  CAS  Google Scholar 

  34. Singh J, Aora A, Garg PK, et al. Antituberculous treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359–62

    Article  PubMed  CAS  Google Scholar 

  35. Pretet S, Perdrizet S. La toxicité du pyrazinamide dans les traitements antituberculeux. Rev Fr Mal Respir 1980; 8: 307–20

    PubMed  CAS  Google Scholar 

  36. Snider DE, Long MW, Cross FS, et al. Six months’ isoniazid and rifampin therapy for pulmonary tuberculosis: report of a USPHS co-operative trial. Am Rev Respir Dis 1984; 129: 573–9

    PubMed  Google Scholar 

  37. Singapore Tuberculosis Services/British Medical Research Council. Clinical trial of six-month regimens of chemotherapy given intermittently in the continuation phase of the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985; 132: 374–8

    Google Scholar 

  38. Geiter LJ, O’Brien RJ, Snider DE. Short-course chemotherapy of pulmonary tuberculosis; preliminary results of USPHS therapy trial 21 [abstract]. Am Rev Respir Dis 1986; 133: A205

    Google Scholar 

  39. Van Aalderen WMC, Knoester H, Knol K. Fulminant hepatitis during treatment with rifampicin, pyrazinamide and ethambutol. Eur J Pediatr 1987; 146: 290–1

    Article  PubMed  Google Scholar 

  40. Whittington RM. Fatal hepatotoxicity of antitubercular chemotherapy. Lancet 1991; 338: 1083–4

    Article  PubMed  CAS  Google Scholar 

  41. Danan G, Pessayre D, Larrey D, et al. Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again [letter]. Lancet 1981; II: 1056

    Google Scholar 

  42. Roden S, Lagneau M, Homasson JP. Hépatite fulminante au pyrazinamide [letter]. Rev Pharm Clin 1990; 46: 43

    CAS  Google Scholar 

  43. Stricker BHC. Drug-induced hepatic injury, 2nd ed. Amsterdam: Elsevier, 1992: 237–47

    Google Scholar 

  44. Hautekeete ML, Kockx MM, Naegels S, et al. Cholestatic hepatitis related to quinolones: a report of 2 cases. J Hepatol 1995; 23: 759–63

    Article  PubMed  CAS  Google Scholar 

  45. Simpson DG, Walker JH. Hypersensitivity to para-aminosalicylic acid. Am J Med 1960; 29: 297–306

    Article  Google Scholar 

  46. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculous therapy: clinical profile and reintroduction therapy. J Clin Gastroenterol 1996; 22: 211–4

    Article  PubMed  CAS  Google Scholar 

  47. British Thoracic Association. A controlled trial of six months’ chemotherapy in pulmonary tuberculosis: first report: results during chemotherapy. Br J Dis Chest 1981; 75: 141–53

    Article  Google Scholar 

  48. Lees AW, Allan GW, Smith J, et al. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182–90

    Article  PubMed  CAS  Google Scholar 

  49. Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118: 461–6

    PubMed  Google Scholar 

  50. Steele MA, Burk RF, Desprez MN. Toxic hepatitis with isoniazid and rifampicin: a meta-analysis. Chest 1991; 99: 465–71

    Article  PubMed  CAS  Google Scholar 

  51. Jenner PJ, Ellerd GA. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70: 93–101

    Article  PubMed  CAS  Google Scholar 

  52. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis [letter]. N Engl J Med 1994; 330: 1241

    Article  PubMed  CAS  Google Scholar 

  53. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990; 113: 799–800

    PubMed  CAS  Google Scholar 

  54. Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408–11

    Article  PubMed  CAS  Google Scholar 

  55. Ozick LA, Lee TP, Jacob L, et al. Early hepatotoxicity from antituberculous treatment in alcoholics and AIDS patients [abstract]. Hepatology 1991; 14: 275A

    Google Scholar 

  56. Cross FS, Long MW, Banner AS, et al. Rifampicin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a US public health service cooperative therapy trial. Am Rev Respir Dis 1980; 122: 349–53

    PubMed  CAS  Google Scholar 

  57. Franks AL, Binkin NJ, Snider DE, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104: 151–5

    PubMed  CAS  Google Scholar 

  58. Kumar A, Misra PK, Mehrotra R, et al. Hepatotoxicity of rifam picin and isoniazid: is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143: 1350–2

    PubMed  CAS  Google Scholar 

  59. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502–4

    PubMed  CAS  Google Scholar 

  60. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid deaths in one state. Am Rev Respir Dis 1989; 140: 700–5

    PubMed  CAS  Google Scholar 

  61. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97–106

    Article  PubMed  CAS  Google Scholar 

  62. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculous drugs. Thorax 1996; 51: 111–3

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hépatologie and INSERM U-24, Hôpital Beaujon, 100 Boulevard du Général Leclerc, 92118, Clichy, France

    François Durand, Dominique Pessayre & Jacques Bernuau

  2. Service de Pneumologie, Hôpital Beaujon, Clichy, France

    Gilles Jebrak & Michel Fournier

Authors
  1. François Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilles Jebrak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominique Pessayre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Fournier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacques Bernuau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durand, F., Jebrak, G., Pessayre, D. et al. Hepatotoxicity of Antitubercular Treatments. Drug-Safety 15, 394–405 (1996). https://doi.org/10.2165/00002018-199615060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615060-00004

Keywords

Search

Navigation